Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Subscribe To Our Newsletter & Stay Updated